dermatology

Phosphagenics Announces Positive Proof of Concept Results from Studies Utilizing Company's Dermal Drug Delivery Technology

...r consumers, which is our objective in theareas of dermatology and cosmetics." In addition to improving the dermal delivery of retinoic acid,Phosphagenics sees broader applications for its TPM-02 technologywith additional pre-clinical studies showing potential in thedermal delivery of other compounds, such as c...

Barrier Therapeutics Announces Liarozole Phase 2/3 Study Results in Lamellar Ichthyosis

... a pharmaceuticalcompany that develops and markets dermatology products, todayannounced results from its completed Phase 2/3 study of liarozolein lamellar ichthyosis, a rare genetic disorder (incidence ofapproximately 1 in 200,000) which is characterized by a thickscaling of the skin over large body areas. Study...

DUSA Pharmaceuticals Receives Orphan Drug Desi gnation for Levulan PDT to Treat Esophage al Dysplasia

...herapy (PDT) technologyplatform, and complementary dermatology products. Levulan PDT iscurrently indicated for the treatment of minimally to moderatelythick actinic keratoses (Grade 1 or 2) of the face or scalp, and isbeing studied for the treatment of acne. DUSA's other dermatologyproducts include ClindaReach(T...

Efficacy and Safety Profile of Basilea's Alitretinoin for Severe Refractory Chronic Hand Eczema Confirmed by Data Shown at European Dermatology Congress

... to fight drugresistance and on the development of dermatology drugs. Basilea'sproducts are targeted to satisfy high medical and patient needs inthe hospital and specialty care setting. The company owns adiversified portfolio including three investigational phase IIIdrugs of which two have shown positive pivotal...

Quest PharmaTech's Prostate Cancer Program Update

...duct, SL017, is atopical formulation indicated for dermatology applications. Theutility of SL017 has already been demonstrated for hair removalapplications in a Phase I clinical trial. In Jan 2007, the Companyinitiated a fifty patient pivotal clinical trial for the sameindications. In addition, SL017 is currentl...

Evaluating the Efficacy and Safety of Once-Daily Anti-Inflammatory Dose Doxycycline for the Treatment of Rosacea

...ng proprietary,innovative medical therapies to the dermatology market. In July2006, CollaGenex launched Oracea(R)...the treatment of rosacea. CollaGenex'sprofessional dermatology sales force also markets Pandel(R), aprescription topical corticosteroid licensed from Altana, Inc.,...

Basilea Reports Positive Re-treatment Results from a Second Phase III Trial of Alitretinoin for Patients with Severe Chronic Hand Eczema

... to fight drugresistance and on the development of dermatology drugs. Basilea'sproducts are targeted to satisfy high medical and patient needs inthe hospital and specialty care setting. The company owns adiversified portfolio including three investigational phase IIIdrugs of which two have shown positive pivotal...

Helix BioMedix to Discuss Potential of Its Proprietary Peptides at the BIO International Convention

...infectiveswith a focus on the large anti-infective dermatology market,including indications such as acne and dermatitis. The company alsohopes to increase the number of peptide-enhanced personal careproducts that contain Helix BioMedix peptides in the next severalyears. The Biotechnology Industry Organization (...

ArteFill 5-Year Data to Be Presented at American Society for Aesthetic Plastic Surgery Annual Meeting

...w category ofaesthetic injectable products for the dermatology and plasticsurgery markets. There were approximately two million dermal fillerprocedures in the U.S. in 2006, an increase of 25% over the prioryear, according to the American Society for Aesthetic PlasticSurgery, or ASAPS. The Company's initial produ...

Scientific Results Presented At ECCMID Demonstrate Well- Differentiated Profile of Basilea's Two Phase III Anti- infective Compounds

... to fight drug resistance and on thedevelopment of dermatology drugs. Basilea's products are targetedto satisfy high medical and patient needs in the hospital andspecialty care setting. The company owns a diversified portfolioincluding three investigational phase III drugs of which two haveshown positive pivotal...

Study in Cell by Magen BioSciences Co-Founder David E. Fisher Identifies New Roles in Skin Cancer Prevention for Key Tumor Suppressor Protein

...-Mar 8, 2007 - Magen BioSciences,Inc., a specialty dermatology company, today announced thepublication of a paper in the March 9, 2007 issue of the journalCell by its co-founder and board member, David E. Fisher, M.D.,Ph.D., that identifies two new functions for an important protein,p53, in the pigmentation of s...